Importantly, two strategies improved tumor control: in vivo cathepsin inhibition combined with RT, as well as Ythdf1 deletion or inhibition in tumor antigen–loaded DC vaccines delivered to mice receiving RT (10). The gene discussed is YTHDF1; the disease is neoplasm.